Edwards Lifesciences Corp. Given “Hold” Rating at RBC Capital (EW)
Edwards Lifesciences Corp. (NYSE:EW)‘s stock had its “hold” rating reaffirmed by investment analysts at RBC Capital in a note issued to investors on Tuesday, StockRatingsNetwork reports. They currently have a $75.00 price objective on the stock. RBC Capital’s price target suggests a potential upside of 2.40% from the company’s current price.
Shares of Edwards Lifesciences Corp. (NYSE:EW) traded up 0.12% during mid-day trading on Tuesday, hitting $73.33. 396,861 shares of the company’s stock traded hands. Edwards Lifesciences Corp. has a 1-year low of $62.34 and a 1-year high of $110.79. The stock has a 50-day moving average of $71.68 and a 200-day moving average of $72.98. The company has a market cap of $8.233 billion and a price-to-earnings ratio of 21.41.
Edwards Lifesciences Corp. (NYSE:EW) last issued its quarterly earnings data on Monday, October 28th. The company reported $0.68 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.66 by $0.02. The company had revenue of $496.00 million for the quarter, compared to the consensus estimate of $490.96 million. During the same quarter in the prior year, the company posted $0.58 earnings per share. The company’s quarterly revenue was up 10.6% on a year-over-year basis. On average, analysts predict that Edwards Lifesciences Corp. will post $3.07 earnings per share for the current fiscal year.
A number of other firms have also recently commented on EW. Analysts at Canaccord Genuity raised their price target on shares of Edwards Lifesciences Corp. from $90.00 to $94.00 in a research note to investors on Tuesday. They now have a “buy” rating on the stock. Separately, analysts at Citigroup Inc. upgraded shares of Edwards Lifesciences Corp. from a “neutral” rating to a “buy” rating in a research note to investors on Wednesday, October 16th. They now have a $86.00 price target on the stock, up previously from $75.00. Finally, analysts at Stifel Nicolaus raised their price target on shares of Edwards Lifesciences Corp. from $81.00 to $82.00 in a research note to investors on Thursday, October 3rd. They now have a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, nine have given a hold rating and thirteen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $78.47.
Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.